Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Bladder Neoplasms | 10 | 2024 | 376 | 4.090 |
Why?
|
Antineoplastic Agents, Immunological | 6 | 2022 | 185 | 2.460 |
Why?
|
Programmed Cell Death 1 Receptor | 5 | 2019 | 159 | 1.940 |
Why?
|
Immunotherapy | 13 | 2023 | 627 | 1.930 |
Why?
|
Neoplasms | 15 | 2023 | 2889 | 1.870 |
Why?
|
Tumor Microenvironment | 9 | 2024 | 415 | 1.660 |
Why?
|
Kidney Neoplasms | 5 | 2024 | 620 | 1.300 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2016 | 155 | 1.040 |
Why?
|
Carcinoma, Renal Cell | 4 | 2024 | 425 | 1.010 |
Why?
|
B7-H1 Antigen | 4 | 2019 | 250 | 0.940 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2020 | 21 | 0.920 |
Why?
|
Antibodies, Monoclonal, Humanized | 5 | 2024 | 929 | 0.810 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2021 | 371 | 0.800 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2021 | 89 | 0.770 |
Why?
|
Urothelium | 1 | 2020 | 68 | 0.750 |
Why?
|
Immunity | 2 | 2019 | 134 | 0.720 |
Why?
|
Biomarkers, Tumor | 5 | 2020 | 1461 | 0.720 |
Why?
|
HLA Antigens | 1 | 2021 | 232 | 0.720 |
Why?
|
Venae Cavae | 1 | 2019 | 14 | 0.700 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2019 | 164 | 0.680 |
Why?
|
Molecular Targeted Therapy | 2 | 2020 | 266 | 0.660 |
Why?
|
Antigens, Neoplasm | 2 | 2020 | 324 | 0.660 |
Why?
|
Ascites | 1 | 2018 | 55 | 0.640 |
Why?
|
Biopsy | 3 | 2016 | 1160 | 0.630 |
Why?
|
Sulfonamides | 2 | 2016 | 299 | 0.620 |
Why?
|
T-Lymphocytes | 3 | 2021 | 1195 | 0.590 |
Why?
|
CTLA-4 Antigen | 1 | 2017 | 135 | 0.580 |
Why?
|
Membrane Proteins | 1 | 2023 | 1194 | 0.560 |
Why?
|
Venous Thrombosis | 1 | 2019 | 242 | 0.560 |
Why?
|
Carcinoma | 1 | 2019 | 434 | 0.560 |
Why?
|
Humans | 38 | 2024 | 86281 | 0.510 |
Why?
|
Angiogenesis Inhibitors | 1 | 2016 | 309 | 0.480 |
Why?
|
Precision Medicine | 1 | 2018 | 394 | 0.480 |
Why?
|
Pyrimidines | 1 | 2016 | 370 | 0.470 |
Why?
|
Silicic Acid | 1 | 2013 | 1 | 0.470 |
Why?
|
Aluminum Hydroxide | 1 | 2013 | 3 | 0.470 |
Why?
|
Antacids | 1 | 2013 | 4 | 0.470 |
Why?
|
Magnesium Oxide | 1 | 2013 | 4 | 0.470 |
Why?
|
Sodium Bicarbonate | 1 | 2013 | 10 | 0.460 |
Why?
|
Alginates | 1 | 2013 | 15 | 0.460 |
Why?
|
Postprandial Period | 1 | 2013 | 47 | 0.450 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 123 | 0.450 |
Why?
|
Practice Patterns, Physicians' | 1 | 2018 | 578 | 0.440 |
Why?
|
Tuberculosis, Lymph Node | 1 | 2011 | 3 | 0.410 |
Why?
|
Actinomyces | 1 | 2011 | 5 | 0.410 |
Why?
|
Granuloma, Plasma Cell | 1 | 2011 | 9 | 0.410 |
Why?
|
Actinomycosis | 1 | 2011 | 12 | 0.410 |
Why?
|
Gastroesophageal Reflux | 1 | 2013 | 117 | 0.400 |
Why?
|
Lymphoma | 2 | 2023 | 262 | 0.380 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 1073 | 0.370 |
Why?
|
Neoplasms, Second Primary | 2 | 2023 | 252 | 0.360 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2023 | 314 | 0.350 |
Why?
|
beta Catenin | 3 | 2021 | 250 | 0.320 |
Why?
|
Breast Neoplasms | 3 | 2022 | 2881 | 0.310 |
Why?
|
Magnetic Resonance Imaging | 3 | 2019 | 3347 | 0.310 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2021 | 295 | 0.310 |
Why?
|
Lymph Nodes | 1 | 2011 | 530 | 0.310 |
Why?
|
Melanoma | 2 | 2023 | 454 | 0.300 |
Why?
|
Lung Neoplasms | 2 | 2019 | 2260 | 0.300 |
Why?
|
Indazoles | 2 | 2016 | 68 | 0.280 |
Why?
|
Lymphocyte Activation | 2 | 2021 | 727 | 0.280 |
Why?
|
Organosilicon Compounds | 1 | 2004 | 4 | 0.250 |
Why?
|
Silver | 1 | 2004 | 16 | 0.250 |
Why?
|
Alkynes | 1 | 2004 | 17 | 0.250 |
Why?
|
Treatment Outcome | 6 | 2021 | 7949 | 0.230 |
Why?
|
Wnt Signaling Pathway | 2 | 2021 | 89 | 0.230 |
Why?
|
Clinical Trials as Topic | 2 | 2019 | 1168 | 0.220 |
Why?
|
Capecitabine | 2 | 2024 | 95 | 0.220 |
Why?
|
Disease Progression | 2 | 2018 | 1531 | 0.220 |
Why?
|
Gene Expression Profiling | 3 | 2018 | 1381 | 0.220 |
Why?
|
Maytansine | 1 | 2022 | 9 | 0.220 |
Why?
|
Urinary Bladder | 1 | 2024 | 236 | 0.210 |
Why?
|
Cisplatin | 2 | 2024 | 612 | 0.200 |
Why?
|
Immunoconjugates | 1 | 2022 | 106 | 0.200 |
Why?
|
Middle Aged | 8 | 2021 | 24957 | 0.200 |
Why?
|
Female | 12 | 2024 | 44405 | 0.200 |
Why?
|
Cellular Reprogramming | 1 | 2021 | 37 | 0.200 |
Why?
|
Phenylurea Compounds | 1 | 2021 | 113 | 0.190 |
Why?
|
Quinolines | 1 | 2021 | 95 | 0.190 |
Why?
|
Antibodies, Monoclonal | 2 | 2017 | 1376 | 0.190 |
Why?
|
Neoadjuvant Therapy | 2 | 2019 | 315 | 0.180 |
Why?
|
Immunomodulation | 2 | 2018 | 55 | 0.180 |
Why?
|
Immunity, Innate | 1 | 2023 | 405 | 0.180 |
Why?
|
Killer Cells, Natural | 1 | 2021 | 267 | 0.170 |
Why?
|
Aged | 8 | 2024 | 18353 | 0.160 |
Why?
|
Microbiota | 1 | 2023 | 378 | 0.160 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2021 | 1196 | 0.160 |
Why?
|
Clinical Decision-Making | 1 | 2020 | 255 | 0.160 |
Why?
|
Germ-Line Mutation | 1 | 2021 | 329 | 0.160 |
Why?
|
Cell Proliferation | 2 | 2021 | 1571 | 0.160 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2018 | 59 | 0.160 |
Why?
|
Urologic Neoplasms | 1 | 2018 | 77 | 0.160 |
Why?
|
Gastrointestinal Microbiome | 1 | 2023 | 451 | 0.150 |
Why?
|
Positron Emission Tomography Computed Tomography | 1 | 2018 | 86 | 0.150 |
Why?
|
Mutation | 3 | 2019 | 3952 | 0.150 |
Why?
|
Costimulatory and Inhibitory T-Cell Receptors | 1 | 2016 | 1 | 0.150 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2018 | 236 | 0.150 |
Why?
|
Ipilimumab | 1 | 2017 | 58 | 0.150 |
Why?
|
Therapies, Investigational | 1 | 2016 | 17 | 0.150 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 589 | 0.150 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 476 | 0.150 |
Why?
|
Animals | 7 | 2023 | 26518 | 0.140 |
Why?
|
Tumor Escape | 1 | 2016 | 49 | 0.140 |
Why?
|
Chemoradiotherapy | 1 | 2018 | 301 | 0.140 |
Why?
|
Antigen-Presenting Cells | 1 | 2016 | 139 | 0.140 |
Why?
|
PPAR gamma | 1 | 2016 | 66 | 0.140 |
Why?
|
Patient Selection | 1 | 2019 | 685 | 0.140 |
Why?
|
Adjuvants, Immunologic | 1 | 2016 | 166 | 0.140 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2016 | 262 | 0.140 |
Why?
|
Prognosis | 2 | 2020 | 3669 | 0.130 |
Why?
|
Cluster Analysis | 1 | 2016 | 369 | 0.130 |
Why?
|
Recurrence | 1 | 2018 | 1137 | 0.130 |
Why?
|
Receptors, Estrogen | 1 | 2016 | 382 | 0.130 |
Why?
|
Administration, Oral | 1 | 2016 | 683 | 0.130 |
Why?
|
Central Venous Catheters | 1 | 2014 | 23 | 0.130 |
Why?
|
Crohn Disease | 1 | 2021 | 729 | 0.120 |
Why?
|
Cohort Studies | 1 | 2021 | 2759 | 0.120 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2018 | 556 | 0.120 |
Why?
|
Colitis, Ulcerative | 1 | 2021 | 708 | 0.120 |
Why?
|
Awareness | 1 | 2014 | 92 | 0.120 |
Why?
|
Medical Staff, Hospital | 1 | 2014 | 107 | 0.120 |
Why?
|
Gene Regulatory Networks | 1 | 2016 | 291 | 0.120 |
Why?
|
Esophageal pH Monitoring | 1 | 2013 | 12 | 0.120 |
Why?
|
Manometry | 1 | 2013 | 43 | 0.120 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 532 | 0.110 |
Why?
|
Hospitalization | 1 | 2018 | 844 | 0.110 |
Why?
|
Electric Impedance | 1 | 2013 | 104 | 0.110 |
Why?
|
Male | 8 | 2024 | 40860 | 0.110 |
Why?
|
Drug Combinations | 1 | 2013 | 222 | 0.110 |
Why?
|
Neoplasm Metastasis | 1 | 2016 | 1056 | 0.110 |
Why?
|
Cross-Over Studies | 1 | 2013 | 399 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 2 | 2019 | 2594 | 0.110 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2013 | 493 | 0.110 |
Why?
|
Cystectomy | 2 | 2024 | 93 | 0.100 |
Why?
|
Contrast Media | 1 | 2016 | 1076 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2434 | 0.100 |
Why?
|
Antineoplastic Agents | 1 | 2022 | 2351 | 0.100 |
Why?
|
Neovascularization, Pathologic | 1 | 2012 | 352 | 0.090 |
Why?
|
Endothelium, Vascular | 1 | 2012 | 435 | 0.090 |
Why?
|
Signal Transduction | 2 | 2021 | 3233 | 0.090 |
Why?
|
Aged, 80 and over | 2 | 2018 | 6481 | 0.090 |
Why?
|
Databases, Genetic | 2 | 2021 | 259 | 0.090 |
Why?
|
Clinical Competence | 1 | 2014 | 750 | 0.080 |
Why?
|
Double-Blind Method | 1 | 2013 | 1822 | 0.080 |
Why?
|
Adult | 4 | 2022 | 25577 | 0.080 |
Why?
|
Combined Modality Therapy | 2 | 2024 | 1680 | 0.080 |
Why?
|
Inflammation | 1 | 2012 | 913 | 0.070 |
Why?
|
Diagnosis, Differential | 1 | 2011 | 1562 | 0.070 |
Why?
|
Mice | 4 | 2023 | 11313 | 0.070 |
Why?
|
Cyclization | 1 | 2004 | 10 | 0.060 |
Why?
|
Phenotype | 2 | 2021 | 2375 | 0.060 |
Why?
|
Catalysis | 1 | 2004 | 203 | 0.060 |
Why?
|
Perforin | 1 | 2023 | 55 | 0.060 |
Why?
|
Molecular Structure | 1 | 2004 | 287 | 0.060 |
Why?
|
Disease Models, Animal | 2 | 2021 | 2227 | 0.060 |
Why?
|
Neoplasm Invasiveness | 1 | 2024 | 551 | 0.050 |
Why?
|
Cells, Cultured | 2 | 2021 | 2810 | 0.050 |
Why?
|
Retinoblastoma-Like Protein p107 | 1 | 2021 | 2 | 0.050 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2021 | 19 | 0.050 |
Why?
|
T Cell Transcription Factor 1 | 1 | 2021 | 23 | 0.050 |
Why?
|
Maximum Tolerated Dose | 1 | 2022 | 270 | 0.050 |
Why?
|
Models, Theoretical | 1 | 2023 | 480 | 0.050 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 80 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2020 | 64 | 0.050 |
Why?
|
Europe | 1 | 2021 | 308 | 0.050 |
Why?
|
Interferons | 1 | 2021 | 132 | 0.050 |
Why?
|
Wnt Proteins | 1 | 2021 | 123 | 0.050 |
Why?
|
Quantitative Trait, Heritable | 1 | 2021 | 124 | 0.050 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2019 | 28 | 0.050 |
Why?
|
Forkhead Transcription Factors | 1 | 2021 | 166 | 0.050 |
Why?
|
Margins of Excision | 1 | 2019 | 39 | 0.050 |
Why?
|
Genes, BRCA1 | 1 | 2021 | 192 | 0.040 |
Why?
|
Patient Advocacy | 1 | 2019 | 49 | 0.040 |
Why?
|
Advisory Committees | 1 | 2019 | 90 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2019 | 116 | 0.040 |
Why?
|
Adoptive Transfer | 1 | 2018 | 168 | 0.040 |
Why?
|
Lymph Node Excision | 1 | 2019 | 211 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 1305 | 0.040 |
Why?
|
Mice, Transgenic | 1 | 2021 | 1537 | 0.040 |
Why?
|
Cytokines | 1 | 2021 | 775 | 0.040 |
Why?
|
Remission Induction | 1 | 2018 | 722 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2021 | 1801 | 0.040 |
Why?
|
Immunohistochemistry | 1 | 2020 | 1752 | 0.040 |
Why?
|
Patient Safety | 1 | 2018 | 212 | 0.030 |
Why?
|
Medical Oncology | 1 | 2019 | 357 | 0.030 |
Why?
|
Societies, Medical | 1 | 2019 | 572 | 0.030 |
Why?
|
Neoplasm Staging | 1 | 2020 | 1932 | 0.030 |
Why?
|
Catheter-Related Infections | 1 | 2014 | 23 | 0.030 |
Why?
|
Personnel, Hospital | 1 | 2014 | 30 | 0.030 |
Why?
|
Survival Rate | 1 | 2018 | 1856 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2021 | 3087 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 1611 | 0.030 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2012 | 63 | 0.030 |
Why?
|
Time Factors | 1 | 2021 | 5198 | 0.030 |
Why?
|
Biomarkers | 1 | 2018 | 1709 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2014 | 377 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 2267 | 0.030 |
Why?
|
Inpatients | 1 | 2014 | 295 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2018 | 3616 | 0.030 |
Why?
|
Intensive Care Units | 1 | 2014 | 373 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2012 | 689 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 859 | 0.020 |
Why?
|
Glioma | 1 | 2012 | 285 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2012 | 997 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2012 | 427 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2014 | 1610 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2012 | 683 | 0.020 |
Why?
|
United States | 1 | 2021 | 6637 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 2012 | 554 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2012 | 2421 | 0.020 |
Why?
|
Internship and Residency | 1 | 2014 | 1001 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2018 | 8431 | 0.020 |
Why?
|